West Haven Criteria

Grading of Hepatic Encephalopathy — Covert and Overt HE
Standardised five-grade system for hepatic encephalopathy severity. Used in clinical practice, research, and treatment guidelines. Guides decision-making from outpatient management to ICU admission and liver transplant evaluation.
Hepatology Encephalopathy Cirrhosis Neurology ICU
Select Clinical Grade

Select the grade that best describes the patient's current neurological status:

West Haven Grade
Select a grade above and confirm

Grade Descriptions

Grade Consciousness Orientation Asterixis Key Features
0 Normal Normal Absent Abnormal on psychometric testing only
1 Normal Normal May be absent Shortened attention, sleep disturbance
2 Lethargic Disoriented for time Present Personality change, inappropriate behaviour
3 Semi-stupor Grossly disoriented Usually present Responds to stimuli only
4 Coma Absent (coma) No response to pain/voice

Management by Grade

Grade Setting Key Interventions
0–1 Outpatient Treat precipitants, lactulose, dietary protein advice, rifaximin if recurrent
2 Inpatient ward Lactulose, rifaximin, treat all precipitants, monitor airway
3 HDU / ICU Airway protection, NG lactulose, rifaximin, urgent precipitant treatment
4 ICU (intubate) Intubation, lactulose via NGT, rifaximin, manage cerebral oedema, transplant evaluation

Common Precipitants

  • Gastrointestinal bleeding (most common — increases intestinal ammonia)
  • Infection (SBP, UTI, pneumonia — look for fever, leucocytosis)
  • Constipation
  • Electrolyte disturbance (hyponatraemia, hypokalaemia)
  • Benzodiazepine or sedative use
  • Renal failure (hepatorenal syndrome, dehydration)
  • Excessive dietary protein
  • Portosystemic shunts (TIPS, surgical)

Covert vs Overt HE

  • Covert HE (Grade 0, also called Minimal HE): only detectable with psychometric tests — Number Connection Test (NCT-A, NCT-B), Critical Flicker Frequency, Inhibitory Control Test
  • Overt HE: Grades 1–4, clinically detectable
  • Covert HE affects driving, quality of life, and predicts future overt episodes

Lactulose and Rifaximin

  • Lactulose: first-line; titrate to 2–3 soft stools/day; over-purgation causes hypernatraemia
  • Rifaximin 550 mg BD: significantly reduces recurrence of overt HE (NEJM 2010, Bass NM et al.); now standard second-line/combined agent

References

  1. Ferenci P, et al. Hepatic encephalopathy — definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35(3):716–721.
  2. Vilstrup H, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the AASLD and EASL. Hepatology. 2014;60(2):715–735.
  3. Bass NM, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–1081.